A new ultra-low-dose combination oral contraceptive.
Data were compiled from 17 U.S. sites during a study of levonorgestrel, 0.15 mg, and ethinyl estradiol, 0.03 mg. A total of 1,130 women participated in 11,604 cycles of treatment. Efficacy, cycle characteristics, bleeding irregularities and side effects were studied. Weight and blood pressure means were analyzed with the paired t-test. Subject acceptance of this new combination oral contraceptive was high.
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D016912:Levonorgestrel; D008598:Menstruation / Q000187:drug effects; D009644:Norgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D013237:Stereoisomerism
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D009644:Norgestrel; D004997:Ethinyl Estradiol; D016912:Levonorgestrel